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CASE REPORT
Peripheral primitive neuroectodermal tumor
(PNET) was first reported by Stout in 1918, who
presumed the condition to be of neuroectodermal
origin, most often presenting as a bone or soft
tissue mass in adolescents and young adults.1
Primary PNET arising from the urinary tract is
rare, with only sporadic case reports. Here, we
report two cases of primary renal PNET and one
case of primary ureteral PNET.
Case Reports
The clinical courses, imaging studies, histologic
features, and outcomes of the three patients are
summarized in the Table.
Case 1
This 44-year-old male presented with gross hema-
turia and left flank pain of 2 months’ duration.
Physical examination and laboratory tests were un-
remarkable. Computed tomography (CT) showed
a heterogeneously enhanced left renal mass
(9 cm in diameter) (Figure A). Bone scan and
chest X-ray revealed no evidence of metastasis.
Laparoscopic radical nephrectomy was performed.
Grossly, the tumor was well demarcated and
showed brown and yellow cut surfaces with focal
hemorrhage and necrosis. Microscopic examina-
tion showed blue round tumor cells with occa-
sional Homer-Wright rosette formation (Figure B).
tImmunohistochemical staining demonstrated tha
the tumor cells were positive for CD99 (1:120,
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monoclonal; Dako, Carpinteria, CA, USA) and
FLI-1 (1:200, polyclonal; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) (Figures C, D), and
negative for actin and cytokeratin. Adjuvant
chemotherapy was given with VAC (vincristine
0.67 mg/day; adriamycin 25 mg/m2/day; cyclo-
phosphamide 1200 mg/m2 r /day; and mesna fo
3 days) for four courses, and IE (etoposide
Table. Clinical and immunohistochemical (IHC) staining data in the three cases
Case
Age
Sex Location Presentation Treatment
Recurrence or Survival
Status
Positive IHC
(yr) metastasis (mo) staining
1 44 M Lt kidney Flank pain, Surgery, No 48 No evidence CD99, FLI-1
hematuria chemotherapy of disease
2 75 F Rt kidney Flank pain, Surgery, Local recurrence 7 Died of NSE, S-100,
hematuria chemotherapy in liver, lung disseminated vimentin,
metastasis FLI-1, CD99
3 45 M Lt ureter Painless Surgery,  Local recurrence 24 Died of NSE, S-100,
hematuria chemotherapy, in lung disseminated CD99, FLI-1
palliative RT metastasis
Lt = left; Rt = right; RT = radiotherapy; NSE = neuron-specific enolase.
A B
DC
iF gure. ( ) d h h l f l ( ) h ddl d l f h l f k dA  Compute  tomograp y s ows a e t rena  mass 9 cm  at t e mi e an  ower portions o  t e e t i ney
with central cystic components (arrow). (B) Monotonous small round blue cells with Homer-Wright rosette formation
(arrow) (hematoxylin and eosin, 400˜). (C) CD99 immunohistochemical stain shows positive membranous stain on
tumor cell cytoplasmic surfaces (ABC method, 400˜). (D) Positive nuclear FLI-1 immunohistochemical stain (ABC
method, 400˜).
100 mg/m2/day; ifosfamide 1800 mg/m2/day for
5 days) for three courses. The patient had no evi-
dence of recurrence at the 4-year follow-up.
Case 2
A 75-year-old female presented with right flank
pain of 2 weeks’ duration. Physical examination
revealed a palpable mass at the right upper 
abdominal quadrant. Laboratory data showed
only anemia (hemoglobin, 9.1 g/dL). Magnetic
resonance imaging showed a 15 ˜ 16 cm, hetero-
geneously enhanced tumor without regional
lymphadenopathy. Right renal vein and inferior
vena cava (IVC) thrombosis extending to the right
atrium were noted on venocavography. Right rad-
ical nephroureterectomy and IVC thrombectomy
were performed with cardiopulmonary bypass.
Grossly, the tumor measured 14.5 cm in diameter,
and the cut surface was grayish white with areas
of necrosis and hemorrhage. The IVC thrombus
was 15.8 ˜ 3.5 ˜ 3.5 cm in size. Microscopically,
the tumor was composed of sheets of loosely co-
hesive small round cells with fine powdery chro-
matin in a perivascular arrangement, or separated
by fibrous bands. Perirenal soft tissue involve-
ment by tumor cells was also noted. Immuno-
histochemically, the tumor cells stained positively
for neuron-specific enolase (NSE), S-100, vimentin,
CD99 and FLI-1, but were negative for cytokeratin,
chromogranin and synaptophysin. No molecular
analysis was performed on the specimen. The
postoperative course was uneventful. Five months
later, CT showed multiple hepatic and pulmonary
nodules consistent with metastasis. Local tumor
recurrence with an IVC thrombus was also noted.
The patient did not receive any adjuvant therapy
and died of disseminated disease 7 months after
diagnosis.
Case 3
A 45-year-old male presented with a 2-month
history of intermittent painless hematuria. Intra-
venous urography (IVU) showed left hydrone-
phrosis with a filling defect in the left lower ureter
and bladder. Cystoscopy revealed a reddish tumor
with a granulated surface protruding from the left
rureteral orifice. Transurethral resection of the tumo
yand laser ablation were performed. Patholog
showed only squamous metaplasia. Three years
later, gross hematuria recurred. Cystoscopy re-
tvealed a recurrent tumor bulging from the lef
ureteral orifice. Left ureteral segmental resection,
partial cystectomy, and ureteroneocystostomy were
performed. Pathology revealed ureteral PNET.
Microscopically, the ureteral tumor was composed
of monotonous medium-sized oval to polygonal
ytumor cells in a sheet-like distribution with slightl
irregular, hyperchromatic nuclei and ill-defined
cytoplasmic borders. Immunohistochemical stain-
ing was positive for NSE, S-100, CD99 and FLI-1,
and negative for synaptophysin, chromogranin,
common leukocyte antigen and cytokeratin.
Recurrence was Tnoted again 7 years later. C
showed left-side hydronephrosis with a huge mass
at the pelvic cavity with adhesion to the bladder,
tpelvic side wall and rectus muscle. Adjuvan
chemotherapy was given with a VAC and IE regi-
men for 3 courses. However, disease progression
with lung metastasis was noted. Other drugs, includ-
ing docetaxel, topotecan and imatinib mesylate,
and palliative radiotherapy with 2800 cGy in 14
fractions, were also given. He died of disseminated
metastasis 2 years after chemotherapy.
Discussion
rPNET is a member of the small round cell tumo
family. PNET arising from the urinary tract is a rare
ydisease that has been documented principall
through case reports.2–7 The differential diagno-
sis includes the other members of this family, such
as extraosseous Ewing’s sarcoma, rhabdomyosar-
coma, Wilms’ tumor, neuroblastoma, etc.5–8 We
analyzed 851 cases of urinary tract malignancy in
your hospital between 1984 and 2004, and onl
three (0.035%) cases of PNET were identified.
Our review of the literature found over 100 cases
tof PNET arising from the urinary tract, and mos
of these cases arose from the kidney. Primary uri-
nary bladder PNET has been reported once and
PNET originating from the ureter (Case 3) has
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not been previously reported.9 Renal PNET and
IVC tumor thrombus has only been reported
four times and our patient (Case 2) is the fifth 
reported case.10–13
Histologically, PNET is characterized by small
round cells that may form Homer-Wright rosettes
or pseudorosettes. PNET can be differentiated
from other small round cell tumors by immuno-
histochemical techniques. PNET may be negative
for S-100, synaptophysin, chromogranin, cyto-
keratin, actin, desmin, and neurofilament. Some
stains, such as CD99, FLI-1 and WT-1, are useful
to confirm the diagnosis. Nearly all PNETs are
strongly CD99 positive, which is a product of the
MIC2 gene. Two recently described nuclear pro-
teins, FLI-1 and WT-1, can discriminate PNET from
other small round cell tumors. Approximately
70% of extrarenal PNETs and 67% of renal
PNETs are positive for FLI-1 antibody.5,6 Most
renal PNETs did not express WT-1, the product of
the WT-1 gene located at 11p13, which is a tran-
scription factor of the tumor suppressor gene.5–8
Approximately 90% of PNETs have a specific
t(11;22)(q24;q12) chromosomal translocation
that results in a unique chimeric protein, EWS-
FLI-1. Using reverse transcription–polymerase
chain reaction, the chimeric gene can be demon-
strated as a highly specific molecular marker.14
All three cases of PNET in this report stained pos-
itively for CD99 and FLI-1.
Most reported cases of PNET typically mani-
fest in children and young adults. Kuroda et al
reported that the average age at diagnosis was
27.7 years.3 Another large series of renal PNET
cases of the kidney showed a wide age spectrum,
ranging from 1 month to 72 years, with a median
age of 18 years.5,6 The two cases of renal PNET in
this report were both much older (44 years and
75 years) than the mean age in previous reported
series.
It is difficult to differentiate renal PNET from
Wilms’ tumor, renal cell carcinoma, and sarco-
matous lesions by imaging studies alone. How-
ever, PNETs are typically noncalcified ill-defined
heterogeneous masses of low attenuation, with
necrotic or hemorrhagic areas and only slight
contrast enhancement in the solid portions on
nonenhanced CT.15
rBecause of the aggressive behavior and poo
prognosis of renal PNET, there has been some de-
tbate about whether renal PNET is an entity distinc
from extrarenal PNET.16–18 Treatment includes sur-
gery, radiotherapy, and multidrug chemotherapy.
Prior reports have shown that renal PNET behaves
more aggressively than extrarenal PNET. Patients
wusually present with an advanced stage and sho  
a poor response to combined-modality therapy.
Most patients with advanced renal PNET die of pro-
gressive disease within 1 year of diagnosis. Given
the highly aggressive behavior of this tumor, adju-
yvant multidrug chemotherapy is still necessar
postoperatively. In Case 1 of this report, radical
surgery for localized disease combined with adju-
vant chemotherapy achieved long-term survival.
PNET of the urinary tract is a rare entity that ap-
rpears to behave more aggressively than at othe
locations. The distinction from other primary ma-
lignancies of the urinary tract is crucial for progno-
rsis. Immunohistochemical staining is helpful fo
diagnosis. Only early diagnosis, radical surgery and
adjuvant chemotherapy can achieve good results.
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